MiR199a and miR126 in myocardium soon after ischemia, which should be tested in additional experiments in vivo. Funding: This study is funded by National Science Centre Poland (NCN) grants: SONATA BIS-3 (UMO-2013/10/E/NZ3/007500) to EZS and PRELUDIUM-11 (UMO-2016/21/N/NZ3/00363) to KKW. Faculty of Biochemistry, Biophysics and Biotechnology of Jagiellonian University can be a partner from the Major National Investigation Center (KNOW) supported by the Ministry of Science and Higher EducationThursday, 03 MayPT07: EV-inspired Therapeutics, Vaccines, and Clinical Trials Chairs: Shilpa Buch; Pia Siljander Place: Exhibit Hall 17:158:PT07.Extrusion of mesenchymal stromal cells produces EV-like vesicles that attenuate allergic airway inflammation Elga Bandeira1; Su Chul Jang2; Kyong-Su Park1; Kristina Johansson1; Cecilia L ser3; Madeleine R inger1; Jan L vall1 University of Gothenburg, Gothenburg, Sweden; 2Krefting Research Centre, Institute of Medicine, University of Gothenburg, Boston, USA; 3Krefting Analysis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, SwedenBackground: Asthma is associated with airflow obstruction and hyperresponsiveness that arises from airway inflammation and remodelling. Cell therapy with mesenchymal stromal cells (MSC) has been shown to attenuate airway inflammation in asthma models. Lately, related effects happen to be observed making use of extracellular vesicles (EVs) released by these cells. Nano-sized vesicles may also be artificially generated from MSC by extrusion, and we get in touch with them exosome-mimetic nanovesicles (NVs). Within this study, we evaluated the effects of MSC-derived EVs and NVs in a murine model of allergic airway inflammation. Procedures: EVs have been obtained through sequential centrifugation of media conditioned by human bone marrow MSC for 24 h. NVs were produced by means of serial extrusion of MSCs. Each E2 Enzymes Proteins manufacturer vesicle types underwent density gradient purification and were quantified through nanoparticle tracking evaluation. C57Bl/6 mice were sensitized to ovalbumin (OVA), randomly divided into OVA (intranasally exposed to one hundred OVA on 5 consecutive days) and handle (exposed to PBS) groups. The mice have been further randomized into groups that received 2E09 EVs or NVs, following the very first OVA/PBS exposure. Results: Regional administration of each EVs and NVs lowered the cellularity and HIV-1 gp160 Proteins site quantity of eosinophils in bronchoalveolar lavage fluid (BALF) of OVA-exposed animals. Also, NVs brought on a reduce within the number of inflammatory cells inside the lung tissue, which was related with reduced levels of CCL24 in BALF and lung tissue. The effectivity of NVs was equivalent when administered intraperitoneally or locally for the airways. Altering the administration route, nevertheless, led to exceptional differences in their biodistribution and to distinct attenuation in particular of IL-13 and CCL24. Summary/conclusion: Our benefits indicate that EVs and NVs derived from MSC have equivalent effects in a murine model of airway allergy. Additionally, artificially generated vesicles is often helpful upon different delivery routes, which, on the other hand, benefits in diverse immunomodulatory effects. Because of the larger yield of vesicles obtained by the extrusion procedure as well as the technical positive aspects it presents, we suggest that NVs is often an alternative to EVs in MSC-based therapies. Funding: The Swedish Heart-Lung Foundation, Sahlgrenska University Hospital, Herman Krefting Foundation Against Asthma/Allergy, CODIAK Biosciences.Exosomes are native se.